Physician profile
Boris Royak
NPI 1528091899
$61,901.56
in general payments reported to CMS, 2019-2025
21 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $10K · 2021: $9,825 · 2022: $5,138 · 2023: $121 · 2024: $1,332 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,036 · Food and Beverage: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,035.62 |
| Food and Beverage | $645.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $35,408.04 | 2019-2023 | Austedo |
| Acadia Pharmaceuticals INC | $20,627.24 | 2019-2023 | Nuplazid |
| Indivior INC. | $2,466.37 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $1,333.65 | 2019-2024 | Spravato |
| Sunovion Pharmaceuticals INC. | $474.59 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $290.93 | 2019-2025 | Rexulti |
| Abbvie INC. | $225.82 | 2021-2024 | Vraylar |
| Lundbeck LLC | $204.06 | 2019-2024 | Rexulti |
| Alkermes, INC. | $193.45 | 2019-2025 | Lybalvi, Aristada |
| Vanda Pharmaceuticals INC. | $175.43 | 2019-2024 | Fanapt, Hetlioz |
| Allergan, INC. | $166.18 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $83.75 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.00 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $38.74 | 2019-2025 | |
| Corium, LLC | $33.99 | 2025 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $30.66 | 2020-2024 | Adzenys Xr-Odt |
| Axsome Therapeutics, INC. | $21.88 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.14 | 2022 | |
| Bausch Health US, LLC | $20.00 | 2019 | |
| Shire North American Group INC | $17.84 | 2019 | |
| Neuronetics, INC. | $13.80 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Royak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.